What's the purpose of this trial?
Many patients are treated for advanced cancer without knowledge of underlying molecular features that might indicate FDA approved therapies or potential eligibility for biomarker-selected clinical trials.
The Strata Trial (STR-001-001) has been initiated by Strata Oncology to evaluate the clinical benefit of systematic comprehensive genomic profiling for participants with advanced cancer using real-world data and endpoints, while assessing the proportion of participants available for clinical trials and approved targeted therapies in advanced and/or aggressive cancers. The Strata Trial uses surplus, or leftover, tumor specimens for molecular profiling and does not require additional study-specific procedures.
This trial is currently open and accepting patients.
You may be able to join this trial if you:
The following criteria is a partial list of reasons why patients may be
eligible to participate in this clinical trial. Further evaluation with a medical professional is
required.
Inclusion Criteria:
* Subjects must be ≥ 18 years of age.
* Subjects must have histologically documented solid tumors (including lymphoma and multiple myeloma).
* Specific criteria for individual tumor types are as follows:
1. Participants with gliomas are eligible at any stage of disease
2. Participants with pancreatic carcinoma are eligible at any stage of disease
3. Participants with rare tumors (i.e. cancer started in an unusual place in the body, it is unusual type and requires special treatment) are eligible at stages II-IV.
4. Participants with other tumor types must have recurrent, relapsed, refractory, metastatic, or advanced stages III or IV cancer.
* Must have an adequate formalin-fixed paraffin-embedded tumor specimen for genomic sequencing.
Additional Trial Information
Enrollment: 500,000 patients (estimated)
View More
